The German pharmaceutical company Bayer has been in the news frequently, though for mostly negative reasons. Recent events revolving around litigation related to its Roundup product have seen shares plunge by more than 20%, and legal rulings ordering billions in damages against the company. Bayer recorded its worst ever performance day, seeing share prices fall to their lowest point in a decade. The company also faced a significant setback as a clinical drug trial failed, contributing further to its share downfall. The stock has lost 28% in value in 2023, making shareholders uncertain about 2024. In response to these challenges, Bayer plans a dividend cut and restructuring of their business model. Despite the overwhelmingly negative coverage, there are a few positive notes. Bayer's Menopause drug has shown positive results in late-stage trials and a Monsanto appeal win briefly boosted shares. The company is also taking steps to focus on pipeline progress despite the challenges they face.
BAYER Stocks News Analytics from Tue, 26 Sep 2023 07:00:00 GMT to Fri, 26 Jul 2024 05:47:25 GMT - Rating -9 - Innovation -5 - Information 8 - Rumor -9